Current results of open revascularization for chronic mesenteric ischemia: A standard for comparison  by Park, Woosup M. et al.
Current results of open revascularization
for chronic mesenteric ischemia: A standard
for comparison
Woosup M. Park, MD,a Kenneth J. Cherry, Jr, MD,a Heidi K. Chua, MD,a Rita C. Clark, RN, BSN,
CVN,a Gregory Jenkins, BS,b William S. Harmsen, MS,b Audra A. Noel, MD,a Jean M. Panneton, MD,a
Thomas C. Bower, MD,a John W. Hallett, Jr, MD,a and Peter Gloviczki, MD,a Rochester, Minn
Objective: Questions remain concerning the optimal site of graft origin and the extent of revascularization necessary to
achieve excellent results for chronic mesenteric ischemia (CMI). Endovascular therapy also is performed for CMI. These
factors prompted us to review our results to provide a current standard.
Methods: Ninety-eight patients who underwent operation for CMI from 1989 to 1998 were reviewed. Patients with acute
ischemia and arcuate ligament syndrome were excluded.
Results: Seventy-six women (78%) and 22 men (22%), with an average age of 66 years (range, 36 to 87 years), participated
in the study. Abdominal pain was present in 95 patients (97%), and weight loss in 92 patients (94%). The superior
mesenteric artery was severely diseased (70% to 99% stenosis or occlusion) in 90 patients (92%), the celiac artery in 81
patients (83%), and both arteries in 76 patients (78%). Bypass grafts were performed in 91 patients (93%), 77 antegrade
and 14 retrograde. Of the other seven patients, five had endarterectomies, one reimplantation, and one patch angioplasty.
Multivessel reconstruction was performed in 79 patients (81%), and single-vessel reconstruction in 19 (19%). Twelve
patients had concomitant aortic reconstruction. Three early graft thromboses were seen. Five hospital deaths occurred
(5.1%); one case had concomitant aortic reconstruction (1/12 versus 4/86; P not significant). All five patients who died
were older than 70 years (5/41 versus 0/57; P  .011). The median follow-up period was 1.9 years (range, 0 to 9.6
years). Follow-up was complete in all survivors. The 1-year, 5-year, and 8-year survival rates were 83%, 63%, and 55%,
respectively. These rates were worse than the rates of the age-matched/gender-matched control subjects (P < .001).
Survival was worse in patients greater than 70 years of age (P .0013). Survival was unaffected by the number of vessels
revascularized. The patients with retrograde grafts had decreased median survival rates (4.0 versus 5.7 years; P  .026),
but they were older (75 versus 65 years; P  .0013). The 1-year and 5-year symptom-free survival rates were 95% and
92%, respectively. Symptoms recurred in six patients (6%): four had recurrent stenosis/occlusion and two had patent
grafts. Symptom-free survival was unaffected by the number of vessels revascularized or by graft orientation.
Conclusion: Operation for CMI was successful for most patients, with low operative mortality and excellent long-term
relief of symptoms. Selective concomitant aortic procedures did not increase mortality rates. The rate of symptomatic
recurrences was not different for single-vessel versus multiple-vessel reconstructions or for antegrade versus retrograde
grafts. Patients older than 70 years had increased operative mortality and decreased survival rates. Endovascular therapy
may be appropriate for this subset of patients. (J Vasc Surg 2002;35:853-9.)
Chronic mesenteric ischemia (CMI) is a morbid disease
that results from progressive stenotic disease of the mesen-
teric vessels. Atherosclerosis is the most common cause,
with fibromuscular dysplasia, polyarteritis nodosa, and
Takayasu’s arteritis representing rare causes. CMI presents
with postprandial abdominal pain, inanition, fear of food,
and weight loss, as do many other abdominal and systemic
illnesses. For that reason, diagnosis is often delayed. Un-
treated, the patients face severe malnutrition and death
from complications of acute mesenteric ischemia (AMI) on
CMI. A 10-year review at the Mayo Clinic of patients with
AMI showed that 43% of these patients had prior symptoms
of untreated CMI.1 A recent study from the Henry Ford
Hospital reported that 52% of patients with AMI had
symptoms of CMI.2
The mesenteric circulation is richly collateralized and
arises from the celiac artery (CA), the superior mesenteric
artery (SMA), and the inferior mesenteric artery (IMA).
CMI is thought to be primarily a disease of the CA and
SMA. Some authors have believed the celiac circulation is
the more important vessel to reconstruct, and others the
SMA.3 Nonetheless, concomitant stenotic disease of the
CA and SMA has been shown to be prevalent in these
patients,4 as is the case in this report. CMI is less frequently
seen in patients with single-vessel disease.
Surgical treatment involves revascularization of the ste-
notic or occluded mesenteric vessels. Inflow may be from
the supraceliac aorta (antegrade reconstruction) or from
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the infrarenal aorta or the common iliac artery (retrograde
reconstruction). Outflow may be to the celiac or more
commonly to the SMA only (single-vessel repair) or to a
combination of CA, SMA, and rarely IMA (multivessel
repair). Controversy surrounds the issues of antegrade ver-
sus retrograde reconstruction and single-vessel versus mul-
tivessel repair. Short-term and mid-term (5 years of fol-
low-up) data show good results for open surgical
revascularization in CMI, but long-term data (5 years of
follow-up) are lacking.
Endovascular therapy also has been used to treat CMI.
Although no prospective randomized control data are avail-
able, studies indicate that in the short term, percutaneous
angioplasty with or without stenting is effective,5,6 al-
though mid-term and long-term data are not available. The
advantage of endovascular therapy is its minimally invasive
nature. Its disadvantages are the need for reintervention
and inferior durability.6 Data are lacking with regard to the
most appropriate patient selective criteria for endovascular
treatment of CMI.
To address these controversies, we reviewed our expe-
rience to determine whether antegrade or retrograde graft
orientation and single-vessel or multivessel revascularization
were associated with improved results. Factors associated with
increased mortality and morbidity rates were determined to
find patient subsets that might have benefitted from a less
morbid procedure. Long-term follow-up data were analyzed
to establish a surgical standard for comparison.
PATIENTS AND METHODS
The clinic records of all patients who underwent surgi-
cal treatment for atherosclerotic CMI between January 1,
1989, and December 31, 1998, were retrospectively re-
viewed. Demographic information, comorbid medical con-
ditions, history and physical findings, diagnostic test find-
ings, operative records, postoperative complications, and
mortality were recorded. Follow-up data were abstracted
from clinic records, letter survey, and telephone interview.
Factors associated with survival were analyzed. Cause of
death was determined from clinic records, autopsy findings,
and death certificates. This study was approved by the
Institutional Review Board of the Mayo Foundation.
For statistical analysis, association between postopera-
tive mortality and risk factors was assessed univariately with
two-sample t test, Wilcoxon rank sum test, and 2 test or
Fisher exact test. Survival rate was estimated with the
Kaplan-Meier method. Comparisons of survival curves
were made with log-rank tests. A multivariate Cox propor-
tional hazards model was constructed with factors found to
be significantly associated with survival on univariate anal-
ysis. All tests were two-tailed. Tests were considered signif-
icant at a P value of less than .05.
RESULTS
Demographics, diagnosis, and operation. From
January 1, 1989, to December 31, 1998, 98 patients, 76
women and 22 men, with a mean age of 67 years (range, 37
to 87 years), underwent operation for CMI. The most
prevalent risk factors were tobacco use in 81 patients (82%)
and hypertension in 61 (63%). Coronary artery disease was
present in 32 patients (33%), and 67 (68%) had symptom-
atic disease in another major vascular bed (coronary, cere-
bral, renal, peripheral). Abdominal pain was present in 95
patients (97%). Weight loss occurred in 92 patients (94%)
and was greater than 10 pounds in 72 patients (73%). All
patients were symptomatic of weight loss or abdominal
pain. Average duration of symptoms was 15 months (range,
1 to 60 months). On examination, most patients were thin
and 56 patients (57%) had epigastric bruits.
All patients underwent arteriography. SMA occlusion
or critical stenosis (70% to 99%) was present in 90 patients
(92%), CA occlusion or stenosis in 81 patients (83%), and
critical disease of both CA and SMA in 76 patients (78%).
Duplex ultrasound scan examination was performed in 38
patients and was consistent with arteriographic findings in
31 patients (82%).
Ninety-one patients (93%) underwent bypass grafting.
Revascularizations were performed with polyester grafts in
86% (Table I). Six patients had vein bypass, and one had
polytetrafluoroethylene grafting. In addition, endarterec-
tomy was performed in five patients, reimplantation in one,
and patch angioplasty in one. Bypass grafting was com-
bined with endarterectomy in six patients, reimplantation
in five, and patch angioplasty in one.
The SMA only was revascularized in 19 patients, 77
patients underwent two-vessel reconstruction (CA and
SMA), and an additional two underwent three-vessel re-
construction (CA and SMA and IMA). Graft inflow was
from the supraceliac aorta (antegrade) in 77 patients, from
the infrarenal aorta in 11 patients, and from the right
common iliac artery in three patients (retrograde). The
right common iliac artery was chosen in these three patients
because of dense supraceliac and infrarenal aortic calcifica-
tion and a soft suitable donor site in the common iliac
artery.
Twelve concomitant procedures were performed (Ta-
ble II). Four AAA repairs and seven aortoiliac occlusive
disease (AIOD) revascularizations were performed. Renal
artery reconstruction was performed in one patient who
Table I. Reconstruction
Type of surgery No. of patients
Polyester graft 84 (85.7%)
Endarterectomy 11 (11.2%)
Vein graft 6 (6.1%)
Reimplantation 6 (6.1%)
Patch angioplasty 3 (3.1%)
Polytetrafluoroethylene graft 1 (1.0%)
Single-vessel revascularization 19 (19.4%)
Two-vessel revascularization 77 (78.6%)
Three-vessel revascularization 2 (2.0%)
Antegrade configuration 77 (78.6%)
Retrograde configuration 14 (14.3%)
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underwent AAA repair and in one of the patients who
underwent aortoiliac occlusive disease reconstruction. In
addition, one patient had concomitant renal artery recon-
struction without aortic reconstruction.
Follow-up was available for a median of 1.9 years
(range, 0 to 9.6 years). All living patients had clinic visit
records or telephone questionnaires.
Perioperative mortality and morbidity. Three pa-
tients died within 30 days of operation. Two more died in
the hospital at 44 and 48 days. Thus, the 30-day mortality
rate was 3.1% and the in-hospital mortality rate was 5.1%.
All hospital deaths occurred in patients older than 70 years
(P  .011). Details are summarized in Table III. Cardiac
ischemia was responsible for 60% of the in-hospital deaths.
Concomitant procedures were not associated with an in-
creased in-hospital mortality rate (P  not significant).
Twenty-one postoperative complications were seen. Venti-
lator dependence/tracheostomy and myocardial infarction
were the most frequent complications (Table IV).
Survival. Thirty-one late deaths occurred (Table V).
Information regarding cause of death was available for 24
patients. Most deaths were the result of cardiac causes (11
patients; 35%). Two patients died of bowel infarction.
Survival rate at 1 year was 83%, at 5 years was 62%, and at 8
years was 55% (Fig 1). These rates were significantly worse
than those of a matched Minnesota white control popula-
tion (P .001). Survival rate was worse for patients greater
than 70 years of age (P  .02). Survival was unaffected by
number of vessels bypassed or by graft orientation. The
patients with retrograde grafts had decreased median sur-
vival (4.0 versus 5.7 years; P .026), but they were older in
comparison with those who received antegrade grafts (75
versus 65 years; P  .0013). When patients older than 70
years who underwent retrograde versus antegrade grafts
were compared, no significant difference in survival was
seen. Comorbid risk factors of current or past tobacco use,
hypertension, and coronary artery disease did not have an
impact on survival in univariate analysis.
Retrograde mesenteric reconstructions were per-
formed in 11 patients who underwent concomitant aortic
reconstruction and originated from the new infrarenal
graft. Retrograde grafting from the common iliac artery
was performed for three patients because of dense calcifica-
tion of the supraceliac and infrarenal abdominal aorta.
These patients had soft iliac vessels. Patients with retro-
grade grafts had a higher prevalence rate of hypertension
compared with those with antegrade grafts (93% versus
57%; P  .011) and a lower prevalence of current or past
tobacco use (57% versus 92%; P  .002).
Recurrence, pain relief, and weight gain. Symptom-
recurrence free survival rate was 98% at 90 days, 95% at 1
year, and 92% at 5 years. Symptoms recurred in six patients
and consisted of abdominal pain in all and weight loss in
two. These symptoms were associated with restenosis in
two patients who underwent percutaneous angioplasty of
SMA stenoses with relief of symptoms. Occlusion of the
SMA graft occurred in two patients. Of these, one patient,
after a failed attempt at angioplasty, underwent two-vessel
reconstruction with symptom relief. The second under-
went patch angioplasty of the occluded SMA graft. Two
patients with recurrent symptoms had patent grafts and
were treated symptomatically. One of these patients was
later found to have Crohn’s disease and the other had
continued pain despite normal findings on endoscopic and
radiologic workup of the gastrointestinal tract. Both were
alive at last follow-up.
During the follow-up period, 74 patients noted some
or complete relief of abdominal pain out of 80 patients
(93%) in whom this was charted or documented with
survey, and 61 patients noted weight gain out of 71 patients
(86%) with documented reference to weight change. In 12
patients, symptom relief was not positively documented in
the chart or with survey and therefore was not included in
the analysis.
Patency. Patency data were not uniformly available. In
the 54 patients who underwent follow-up imaging study,
restenosis of the CA or SMA graft occurred in 11 patients.
Three patients had restenosis or occlusion of both CA and
SMA, and all underwent revision. Five patients had reste-
nosis of the CA only. All of these patients had two-vessel
reconstructions, and none needed reintervention. Three
patients had restenosis of the SMA only. One of these
patients had a single graft to the SMA with a moderate
stenosis and no symptoms. The remaining two patients had
two-vessel reconstruction, and one underwent reinterven-
tion for symptoms. Reintervention was performed only for
symptomatic patients. Symptomatic recurrences occurred
when both limbs of a bifurcated graft became stenotic in
three patients or when a single graft to an SMA become
stenotic in one patient. Stenosis in one limb of a bifurcated
graft did not result in symptoms in seven patients, and no
reintervention was necessitated.
DISCUSSION
Earlier, it was our practice to perform concomitant
aortic/renal reconstruction if the anatomy warranted.4
Thirty-six percent of the patients we operated on between
1981 and 1988 underwent concomitant aortic operation,
and their operative mortality rate was 19%. Simarily, the
group from the Cleveland Clinic report that concomitant
aortic replacement was associated with an increase in major
postoperative morbidity and mortality when those end-
points were considered together.7 Because of that earlier
Table II. Concomitant procedures
No. of patients
AAA repair 4 (28.6%)
Aortobiiliac bypass 4 (28.6%)
Aortobifemoral bypass 3 (21.4%)
Renal revascularization 3 (21.4%)
AAA, Abdominal aortic aneurysm.
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experience, we have tried to limit the operations for pa-
tients with CMI to the mesenteric arteries, if possible. At
times, because of the extent of supraceliac or infrarenal
aortic disease and the pattern of disease, concomitant aortic
repair is believed to be necessary. In this series, 12% of
patients had concomitant aortic surgery and their mortality
rate was no different than the other patients. Foley and
colleagues3 have believed that concomitant aortic recon-
struction with retrograde grafting does not increase mor-
bidity or mortality rates. Our series would lend support to
that. In the group of patients treated between 1981 and
1988, the concomitant aortic reconstructions were in ad-
dition to supraceliac repairs and were, therefore, not essen-
tial for the correction of the mesenteric disease. In these
reported patients, concomitant aortic operation was per-
formed to provide a source of inflow for infrarenal mesen-
teric reconstructions and was, thus, a necessary component
of the repair. Thus, we believe selective simultaneous aortic
reconstruction, done to provide mesenteric inflow, is safe
and provides a necessary and excellent blood source for
retrograde reconstructions. On the other hand, patients
who undergo supraceliac graft reconstructions who have
aortic and renal disease are probably better treated with
staged operations. Five patients in this series with suprace-
liac reconstructions subsequently underwent aortic/renal
reconstructions, and all did well.
In the report from the institution 20 years ago, a high
symptomatic recurrence rate was noted, at 26% overall.8
None of the grafts placed at the Mayo Clinic before 1981
were antegrade. Currently, 78% of the patients who un-
dergo grafting (in addition to the patients who undergo
endarterectomy) have reconstruction in an antegrade man-
ner. The symptom-free survival rate at 5 years is 92%, and
only 6% of patients have had recurrent symptoms (Fig 2).
Attributing the reduction in recurrence to antegrade repair
is impossible in a retrospective study, and certainly in two
retrospective studies separated by 20 years. Nonetheless,
we believe that prograde flow with its reduced turbulence,
the decreased likelihood of graft kinking, and the usual
nondiseased state of the supraceliac aorta contributes to
improved patency and symptom-free survival rates.
We were surprised and pleased to find infrarenal retro-
grade reconstructions worked as well statistically as the
antegrade repairs. The patient longevity was not as great,
but these were older patients. They did not die of mesen-
teric disease. We have concluded that both reconstructions,
properly selected for the patient’s general state of health
and aortic anatomy, work well and provide excellent inflow,
especially with infrarenal aortic reconstruction. A dogmatic
adherence to one type of reconstruction over the other is
probably less beneficial to these patients than an individu-
alized approach. We favor the antegrade reconstruction for
its theoretic advantages and because of its results in our
hands. The group from Oregon has reported excellent
results with retrograde reconstructions.3 Their willingness
to provide excellent inflow with infrarenal grafting proba-
bly accounts for their results. In short, both methods will
work in properly selected patients with appropriate atten-
tion to physiology and anatomy.
That report from the Mayo Clinic 20 years ago recom-
mended complete revascularization (ie, two of two diseased
vessels, three of three diseased vessels) and showed a linear
correlation between recurrence and “incompleteness” of
revascularization.8 Nonetheless, as stated previously, none
of those reconstructions was antegrade. We maintained a
degree of faithfulness to that concept of completeness (ie,
reconstruction of the inferior mesenteric artery) for some
years. However, that IMA reconstruction is not a necessary
Table III. In-hospital mortality
Age (y) Gender Procedure Days to death Cause of death
1 88 Male Aorto-CA graft 4 Cardiac arrest
2 74 Male Aorto-CA-SMA graft 6 AMI
3 75 Female Endarterectomy CA, SMA 12 Cardiac arrest
5 78 Female Aortobiiliac bypass, aorto-SMA
bypass, reimplantation IMA
44 Cardiac arrest
4 75 Female Endarterectomy CA, SMA 48 Multisystem organ failure
Table IV. Morbidity
Complications (major) n (%)
Ventilation dependence/tracheostomy 6 (28.6)
Myocardial infarction 4 (19.0)
Thrombosis 3 (14.3)
Cardiac arrest 3 (14.3)
Wound dehiscence 2 (9.5)
Respiratory arrest 1 (4.8)
Renal failure/hemodialysis 1 (4.8)
Table V. Causes of late death (n  31 patients)
Cause No. of patients
Cardiac 11 (35%)
Unknown 7 (23%)
Cerebrovascular accident 3 (10%)
Cancer 3 (10%)
Bowel infarction 2 (6%)
Malnutrition 1 (3%)
Gastrointestinal hemorrhage 1 (3%)
Multisystem organ failure 1 (3%)
Renal failure 1 (3%)
Hepatitis 1 (3%)
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component for successful and durable mesenteric recon-
struction has become apparent. Further, with supraceliac
repair, the addition of an IMA reconstruction necessitates
concomitant aortic surgery. We do not, except in unusual
cases, attend to the IMA in these patients. Similarly, the
group from the Cleveland Clinic found that completeness
of revascularization was associated with increased mortality
and morbidity rates when these endpoints were considered
together.7
Whether one-vessel (SMA) repair is as beneficial and
durable as two-vessel reconstruction is, of course, debat-
able. The group from Oregon believe SMA reconstruction
alone is all that is necessary. Many of their patients had AMI
rather than CMI.3 For the patients with CMI, the addition
of a celiac reconstruction, especially from the supraceliac
aorta, provides a margin of safety should a late failing or
failed graft occur. Both early and late graft thrombosis of a
single SMA reconstruction is often catastrophic. Because
the disease process involves multiple mesenteric vessels, we
believe that reconstruction should address both the in-
volved CA and SMA in patients at good risk. Despite that
bias, the results in the 19 patients for whom we performed
single-vessel reconstruction only were not statistically dif-
ferent than those for the patients who underwent multiple-
vessel repair.
Endarterectomy has been shown by the group of the
University of California–San Francisco to be durable and an
excellent option for these patients.9 Only five of our pa-
tients (5.1%) underwent endarterectomy alone. It is the
operation of choice if the peritoneal cavity is contaminated
and is preferable, especially in younger patients at good risk,
to a bypass procedure if the supraceliac and the infrarenal
aorta are heavily diseased because it provides the best
source of inflow.
CMI, as all vascular disease, may be treated with endo-
vascular methods. Kasirajan et al6 from the Cleveland Clinic
found a higher symptomatic recurrence rate with their
patients who underwent angioplasty/stenting at 3 years
than in their patients who underwent open conventional
repair and recommended that patients at good risk should
be offered conventional revascularization. We agree with
that recommendation but believe that patients at poor risk
more than 70 years of age should be considered for endo-
vascular repair as a potential first option. All our deaths
occurred in this group. Three of our five patients with
in-hospital deaths had undergone reconstruction of both of
the celiac and the SMA, two with endarterectomy and one
with grafting. In retrospect, these particular patients may
have been better served with a more limited, or tailored
approach, with infrarenal reconstruction of the SMA only.
Patients at high risk, especially those patients greater than
70 years of age, should probably be regarded with an eye to
infrarenal single-vessel reconstruction or to endovascular
repair. The feasibility of either is, of course, dictated by
aortic and mesenteric anatomy. Some of these patients
would no doubt have difficulties in repair with endovascu-
lar techniques because of extensive severe atherosclerosis
involving the aorta and the visceral vessels; nonetheless,
these particular patients are poor candidates for conven-
tional repair also. For them, the necessity for repeat angio-
plasty for recurrent stenosis may be more appealing than
the alternative.
The mortality rate in our patients who underwent
treatment before 1981 was 10%.8 That rate did not im-
prove over the next 7 years; our report from 1988 had an
8.9% mortality rate.3 We have been gratified to find a 3.1%
30-day mortality rate and a 5.1% in-hospital mortality rate
for this series of patients. For our patients, we believe that
offering concomitant aortic/renal reconstructions to se-
lected patients only rather than to all patients with involved
pathologic aortic anatomy has helped improve results.
Whereas 36% of patients were undergoing simultaneous
aortic/renal repair in 1981 to 1988, only 12% are now.
Other factors, such as preoperative coronary angioplasty,
improved anesthetic and intensive care techniques, and
experience over time have undoubtedly played contribut-
ing if unquantified roles.
Fig 1. Survival rates.
Fig 2. Recurrence-free survival rates.
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Although our analysis did not indicate CAD as a signif-
icant independent risk factor, myocardial ischemia is the
leading cause of both in-hospital and late deaths. It is a
particularly vexing problem for patients with the worst of
CMI because their mesenteric anatomy places them at high
risk for bowel infarction after coronary artery bypass graft-
ing. These cases remain problematic.
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DISCUSSION
Dr James Stanley (Ann Arbor, Mich). The results in certain
subsets of these patients may vary, and such differences need to be
accounted for when comparing one surgical technique with an-
other. In the older than 70 years age group, how many had
multiple-vessel versus single-vessel reconstructions? Single-vessel
reconstructions may have been common in certain high-risk el-
derly patients. If such were the case, they would be at higher risk
for early as well as late postoperative failures compared with
younger patients undergoing multiple-vessel reconstructions. In
particular, did the series’ two patients with bowel infarctions and
late deaths have single-vessel or multiple-vessel reconstructions?
Our earlier University of Michigan experience and a prior report
from the Mayo Clinic had a number of deaths, which were more
common following single-vessel reconstructions. These patients
clearly involute their collaterals, and if an acute graft occlusion
occurs at a later time, the previously present collaterals are not
there to protect the intestines.
A disproportionate number of women exist in this experience
compared with that reported by others. Most other series have a
less than 3:2 ratio of women to men, but there is nearly a 4:1 ratio
of women to men in your experience. Did you have a bimodal
distribution of women? In other words, did you have a group of
younger women in the 45 to 50 year age group with isolated
splanchnic arterial disease and then a group closer to 70 years of
age, having what might be considered part of generalized cardio-
vascular arteriosclerosis? If you did, were the younger women
extremely heavy smokers as has been reported by others?
Dr Woosup Park. In terms of the older patients, four re-
ceived multiple-vessel reconstructions, and one received a single-
vessel reconstruction. It is our bias to perform multiple-vessel
bypasses when suitable. As to the age distribution, most of the
female patients were older than 60. Eight of our patients were
younger than 50. We excluded patients with arcuate ligament
syndrome from this paper. Our sex distribution was 4:1 in favor of
the women, and most were smokers with atherosclerosis.
Dr John Blebea (Hershey, Pa). This was a very nice presen-
tation of an excellent experience with only a 5% mortality rate in
this series of patients. I am intrigued because our own experience
with reintervention is much higher than your 4%. Part of the reason
may be that a lot of your stenoses, which were asymptomatic, did
not have a secondary intervention. I have two questions.
First, what is your surveillance protocol? Do you have routine
duplex follow-up in these patients, and at what intervals? There
may be asymptomatic stenoses that you may not be detecting.
Secondly, on such asymptomatic patients, what has been their
prognosis and how much follow-up do you have of them? If you
are doing either a single-vessel or two-vessel bypass and there is
greater than 50% stenosis, we are a little hesitant just watching
those asymptomatic patients and tend to intervene, especially if
two out of two vessels are involved. What is your clinical protocol
for that, and what followup do you have on these asymptomatic
patients with stenoses?
Dr Park. Thank you for the excellent question, Dr Blebea.
Follow-up imaging was not uniformly applied, particularly in the
patients who lived far from the clinic, so patency data were not
available. More recently, we have been following these patients
with annual duplex or computed tomography.
In terms of the asymptomatic patients, we have found they
remain symptom-free and die from causes not related to the gut. In
our follow-up, we found that 10 of 31 late deaths were from
cardiac disease, and the remainder died from other causes, with
only two late bowel infarctions. In this particular experience, the
reinterventions were for primarily the symptomatic patients.
Dr Timothy Hodges (Kansas City, Mo). I enjoyed your
presentation very much. My question has to do with aortic source
of inflow. Sometimes it is difficult to find a good aortic segment. If
you have somebody who has infrarenal disease, which many of
these patients do, would you recommend taking down the dia-
phragm in order to get a good segment of low thoracic or suprace-
liac aorta and adding that morbidity, or would you recommend
replacing the infrarenal aorta and then doing the bypass off that
graft?
Dr Park. In our earlier published series, concomitant aortic
and renal reconstruction was performed when additional disease
was found along with the supraceliac mesenteric reconstruction.
Thirty-six percent of the patients in that series had this combined
repair, and there was an associated 19% mortality. Now, the
tendency is to stage the repairs if there are multiple loci of disease.
If there is infrarenal disease and mesenteric disease, then we will do
the aortic reconstruction and use the infrarenal aortic graft as the
inflow source, and we have had excellent results.
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Dr Robert McLafferty (Springfield, Ill). Given your con-
clusion that there is no difference in the outcome between
multiple-vessel and single-vessel bypass, are you going to be
recommending single-vessel bypass more often? Another paper
published by the Oregon group looked at retrograde and single-
vessel bypass with very, very comparable results to yours in
terms of outcome.
Secondly, you mentioned that the retrograde bypass was asso-
ciated with an increased mortality but that those patients were
older. Is that a univariate analysis? Did you do a multivariate
analysis to look at what different significant univariate results came
out positive?
Dr Park. In terms of multiple-vessel versus single-vessel recon-
struction, our bias is that mesenteric ischemia often results from
multivessel disease, and it is our feeling that these vessels should be
reconstructed, and we have had equally good results compared with
our single-vessel reconstructions. With regard to the second question,
the data are presented from univariate analysis.
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